Enterprise Evidence Report · NR-REPORT-V2.0

Thailand
Neuroscience Intelligence

Thailand neuroscience evidence report: current clinical, research, institution and source-linked intelligence.

Evidence rank #46 of 50 · Data maturity A · Research score 27.4 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.

⚗
37Curated trials
↗
11Recruiting trials
▦
26Publications
⌂
15Institutions

Executive interpretation

Thailand ranks #46 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.

Methodology status

Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.

Methodology →

Leading sponsors

Merck Sharp & Dohme LLC107 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.40 recruiting
Chulalongkorn University21 recruiting
UCB Pharma20 recruiting
Mahidol University20 recruiting
Department of Medical Services Ministry of Public Health of Thailand20 recruiting
Khon Kaen University10 recruiting
International Rescue Committee10 recruiting
Medtronic Neurovascular Clinical Affairs10 recruiting
IRCCS San Raffaele Roma11 recruiting

Disease activity

Parkinsons15trials
Epilepsy7trials
Stroke6trials
Multiple Sclerosis2trials
Pain Neuropathy2trials
Movement Disorders1trials
Anxiety1trials
Autism1trials
Depression1trials
Als1trials

Research institutions

Naresuan UniversityOpenAlexlinked institution
Department of Disease ControlOpenAlexlinked institution
Thammasat UniversityOpenAlexlinked institution
Ramathibodi HospitalOpenAlexlinked institution
King Chulalongkorn Memorial HospitalOpenAlexlinked institution
Mahidol UniversityOpenAlexlinked institution
Prince of Songkla UniversityOpenAlexlinked institution
Chulalongkorn UniversityOpenAlexlinked institution
Piyavate HospitalOpenAlexlinked institution

Clinical evidence trail

NCT07252739KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)RECRUITING
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT07067229Non-invasive Brain Stimulation and Exercise Intervention for Patients With Motor Neuron DiseaseRECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06839482Robotic Rehabilitation of the Upper Limb in Subacute StrokeRECRUITING
NCT06180278Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)ACTIVE_NOT_RECRUITING
NCT06170788Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)RECRUITING
NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)ACTIVE_NOT_RECRUITING
NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)ACTIVE_NOT_RECRUITING
NCT02962414Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentACTIVE_NOT_RECRUITING
NCT06595524Development of the Online Mindfulness-based Intervention (MFU-Mindful Application) for Thai-university StudentsCOMPLETED

Research evidence trail

PUBMEDLong-term causes of death in 888,003 ischemic stroke patients in Thailand: a nationwide retrospective study with 18-year follow-up.2026-12-01
PUBMEDDiagnostic and clinical utility of exome sequencing and chromosomal microarray in children with GDD/iD: a meta-analysis.2026-12-01
PUBMEDPsychological stress-associated ceramide and diacylglyceride lipotoxicity as contributors to first-episode depression pathophysiology: A neuroimmune-metabolic-oxidative stress (NIMETOX) perspective.2026-12-01
PUBMEDUnderrecognized restless legs syndrome in Parkinson's disease: Diagnostic delay, association with sleep burden, and dopaminergic exposure in a Thai cohort.2026-12-01
PUBMEDDiagnostic delay and poor functional outcomes in late-onset NMOSD: A Thai cohort study.2026-11-01
PUBMEDMultimodal assessment of sleep and regional brain volumes in AQP4-IgG-positive neuromyelitis optica spectrum disorder: An exploratory cross-sectional study.2026-11-01
PUBMEDSleep-timing mismatch (MSFsc-lights-off interval) and its association with polysomnographic sleep parameters in a clinical population under a fixed laboratory schedule.2026-11-01
PUBMEDPrevalence and impact of cerebral small vessel lesions in mild cognitive impairment and mild dementia due to Alzheimer's disease patients in memory clinic: Preparation for anti-amyloid therapy in Thailand.2026-10-10
PUBMEDPsychiatric and medical comorbidities in patients with migraine before and during the COVID-19 pandemic in Thailand: a retrospective comparative cohort study of two different clinical groups.2026-10-01
PUBMEDReal-World Functional Gains in Thai Children With Attention-Deficit/Hyperactivity Disorder: A 24-Month Naturalistic Study.2026-10-01
PUBMEDWhen machines see more: Digital technologies, measurement, and meaning in hyperkinetic movement disorders.2026-09-02
PUBMEDClinical Factors and Comorbidities Associated With Uncontrolled Seizures in Children With Epilepsy: A Nationwide Study.2026-09-01

World Bank context

IT.NET.USER.ZSinternet_users_pct90.9% · 2024
NY.GDP.MKTP.CDgdp_current_usd$577.0B · 2025
NY.GDP.PCAP.CDgdp_per_capita_usd$8,057 · 2025
SE.PRM.ENRRschool_enrollment_primary_pct100.73 · 2025
SE.SEC.ENRRschool_enrollment_secondary_pct92.09 · 2025
SH.XPD.CHEX.GD.ZScurrent_health_expenditure_pct_gdp4.5% · 2023
SH.XPD.CHEX.PC.CDcurrent_health_expenditure_per_capita_usd$327 · 2023
SH.XPD.GHED.GD.ZSgovernment_health_expenditure_pct_gdp3.5% · 2023
SP.DYN.CBRT.INbirth_rate_crude8.12 · 2024
SP.POP.TOTLpopulation_total71,619,863 · 2025
SP.URB.TOTL.IN.ZSurban_population_pct62.8% · 2025

Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.

Sources and provenance

ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.

Limitations

Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.